Teleflex Incorporated (NYSE: TFX) today announced results of a new
survey showing that the majority of American men over age 40 are
prescribed multiple medications to treat a variety of conditions,
including benign prostatic hyperplasia (BPH), and that both men and
women are concerned about possible side effects of medications.
BPH, also known as enlarged prostate, is a common non- cancerous
enlargement of the prostate that occurs as men age. The symptoms of
BPH can cause loss of productivity, depression and decreased
quality of life.1
Two recent surveys sponsored by Teleflex Incorporated were
conducted among 1000 men and 1000 women over the age of 40 in the
United States to gather insights about beliefs and behaviors
surrounding current treatment options for BPH as well as to
understand current prescription medication trends more broadly.
The results demonstrated that many men and women surveyed
believe that BPH can only be treated with medication, despite the
availability of alternative treatment options for this common
condition. In addition, the survey found that the majority of
patients are interested in learning about alternative treatment
options to treat their BPH symptoms.
“Americans are prescribed more medication than ever before2
despite the availability of non-drug alternatives for common
conditions like BPH,” said Peter Walter, M.D.,F.A.C.S., of Western
New York Urology Associates in Jamestown, NY. “Medications can
often have more physiological impacts beyond the condition the
prescription aims to treat, interactions among drugs remains
understudied, and clinical data regarding potential side effects of
long-term alpha blocker use is inadequate. Additionally, many men
simply stop treating their BPH symptoms as a result of unpleasant
side effects or an unwillingness to take another pill.”
Patient Jim Ward endured frequent trips to the bathroom for over
two years before having the UroLift® System procedure earlier this
year. “I was already taking daily medication to treat high blood
pressure and cholesterol and I did not want to take any additional
medications,” said Ward, a 57 year-old high school English and
Drama teacher. “I felt exhausted at work all of the time and even
considered early retirement because I was not performing to my
normal standard. It took some time to connect my lack of sleep with
my inability to focus during the day. After my UroLift System
procedure, I feel sharper and more present than I’ve felt in years.
The best part was having the procedure on a Friday afternoon and
returning to work on a Monday morning.”*
Many men and women surveyed were unaware that minimally invasive
procedures are available to treat BPH. Of the participants
surveyed,
- Nearly three in four men with BPH said their doctors discussed
medications as a treatment for their BPH symptoms while fewer than
one in five men were told about minimally invasive outpatient
procedures.
- Among both men and women surveyed, nearly one in four believe
BPH can only be treated with medication.
- 54% of men surveyed who have BPH are using or have used
medication to treat their symptoms.
Compliance data from the survey was consistent with clinical
data3 and 2018 AUA Guidelines that reflect men often discontinue
medication to treat their BPH symptoms due to inconvenience, lack
of efficacy, and unpleasant side effects. Male respondents shared
the following:
- 27% of all men taking BPH medication have stopped taking their
medication.
- 25% of men taking medication to treat their BPH symptoms are
unsatisfied with the effectiveness of their medication.
- 15% of men with BPH who treat their symptoms with medication
are concerned about the side effects of medication (headaches,
dizziness, sexual dysfunction).
- 10% of men with BPH who treat their symptoms with medication
are concerned about having to take another pill every day and the
possible interactions.
- 18% of men with BPH who treat their symptoms with medication
are concerned about taking a pill everyday.
- More than one third of men with BPH taking medication to treat
their BPH symptoms have experienced unpleasant side effects. These
side effects include headaches, dizziness, weakness or lack of
energy (asthenia), ejaculatory dysfunction and erectile
dysfunction.
“While we have seen an increased awareness among men and women
about BPH treatment options beyond medication, the survey results
underscore the continued need to improve patient education about
treatment options,” said Dave Amerson, president of Teleflex
Interventional Urology business unit. “Educating patients about
minimally invasive treatment alternatives such as the UroLift
System – an option that typically does not require ongoing
medication2– is critical given the shortcomings of surgery and
medication. We are pleased that to date more than 175,000 men have
elected this innovative option.”**
BPH affects over 42 million men in the United States alone and
more than 12 million men are under a doctor’s care for the
condition.5,6 More than 40% men in their 50s and over 80% of men
their 70s have BPH.4 If left untreated the condition can worsen
over time and cause permanent bladder damage.7
About the UroLift® SystemThe UroLift® System is
a minimally invasive treatment for lower urinary tract symptoms due
to benign prostatic hyperplasia (BPH). It is indicated for the
treatment of enlarged prostate up to 100cc in men 45 and older. The
UroLift permanent implants, delivered during an outpatient
procedure, relieve prostate obstruction and open the urethra
directly without cutting, heating, or removing prostate tissue. The
UroLift System is the only leading BPH procedure shown to not cause
new onset, sustained erectile or ejaculatory dysfunction.8-10 Most
common adverse events are temporary and can include hematuria,
dysuria, micturition urgency, pelvic pain, and urge incontinence.8
The Prostatic Urethral Lift procedure (using the UroLift System) is
recommended for the treatment of BPH in both the American
Urological Association and European Association of Urology clinical
guidelines. More than 175,000 men have been treated with the
UroLift System in select markets worldwide.** As with any medical
procedure, individual results may vary. Learn more at
www.UroLift.com.
About Teleflex Interventional UrologyThe
Teleflex Interventional Urology Business Unit is dedicated to
developing innovative, minimally invasive and clinically effective
devices that address unmet needs in the field of urology. Our
initial focus is on improving the standard of care for patients
with BPH using the UroLift System, a minimally invasive permanent
implant system that treats symptoms while preserving sexual
function.***8,11 Learn more at www.NeoTract.com.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular and interventional access,
surgical, anesthesia, cardiac care, urology, emergency medicine and
respiratory care.
Teleflex employees worldwide are united in the understanding
that what we do every day makes a difference. For more information,
please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a
common sense of purpose.
Dr. Peter Walter is a paid consultant of NeoTract | Teleflex
Interventional Urology.
*As with any medical procedure, individual results may vary.
**Management estimate based on product sales and average units
per procedure.
***No instances of new, sustained erectile or ejaculatory
dysfunction.
Contacts:
For Teleflex Incorporated: Jake Elguicze, 610.948.2836Treasurer
and Vice President, Investor Relations
Media:Nicole Osmer, 650.454.0504
nicole@healthandcommerce.com
__________________________________1 Speakman et al. 2014 BJUI
International2 Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A.
T., & Giovannucci, E. L. (2015). Trends in Prescription Drug
Use Among Adults in the United States From 1999-2012. JAMA,
314(17), 1818–1831. https://doi.org/10.1001/jama.2015.137663
Cindolo et al., Eur Urol 2015 Sep; 68(3): 418-4254 Roehrborn, et
al., Can J Urol 2017; 24(3): 8802-88135 Berry, J Urol 1984 and 2017
U.S. Census population estimates.6 NeoTract US Market Model
estimates for 2018 based on IMS Health Drug and Procedure data7
Tubaro et al. 2003 Drugs Aging8 Roehrborn, J Urology 2013 LIFT
Study9 AUA BPH Guidelines 2003, 2010, 201810 McVary, J Sex Med
201611 McVary, J Sex Med 2014
MAC01542-01 Rev A
Teleflex (NYSE:TFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Sep 2023 to Sep 2024